"solid tumors, and other genetic or immune disorders. Hematopoietic stem cell transplantation is a critical maneuver for many, with origins dating back to the 1940s from the aftermath of the dropping of the atomic bomb. The first successful donor marrow transplant was performed in 1956. Subsequent investigation has explored the safety and efficacy of hematopoietic stem cell transplantation in special populations, such as older individuals and those with organ dysfunction. As of 2023, this transplantation has never been ...
Read More
"solid tumors, and other genetic or immune disorders. Hematopoietic stem cell transplantation is a critical maneuver for many, with origins dating back to the 1940s from the aftermath of the dropping of the atomic bomb. The first successful donor marrow transplant was performed in 1956. Subsequent investigation has explored the safety and efficacy of hematopoietic stem cell transplantation in special populations, such as older individuals and those with organ dysfunction. As of 2023, this transplantation has never been safer due to ongoing advancements in transplant and supportive care. Innovative cellular therapies for blood cancers have become an important treatment option. For the past 10 years, studies have investigated chimeric antigen receptor (CAR) expression on T lymphocytes. This artificial receptor enables T cells to identify and target cancer cells better and harness the immune system through enhanced immune activation. In 2012, the first child underwent CAR T-cell therapy to treat relapsed acute lymphoblastic leukemia. Further studies have demonstrated the efficacy and safety of CAR T-cell therapy, leading to its improved use in patients with leukemia and lymphomas. Recently approved indications in 2021 and 2022 are for patients with relapsed and refractory multiple myeloma. This second edition of the BMTCN??? Certification Review Manual includes critical updates on CAR T-cell therapies and supportive care considerations, such as updated guidelines for prophylactic antibiotics and immunizations. In addition, an extensive review of newly approved therapies with novel mechanisms of action available to treat and support a variety of toxicities such as nausea, neutropenia, and chronic graft-versus-host disease is included. Finally, innovative procedures that improve post-transplant-related outcomes are highlighted within the chapters. Nurses have been integral to the advancement of transplant science throughout the years, especially in their knowledge of supportive care, side effect management, and patient support and education. Patients look to nurses for prompt assessment and evaluation of side effects, which range from mild to severe and life-threatening emergencies. The Oncology Nursing Certification Corporation and Oncology Nursing Society recognize the crucial role of oncology nurses and support the validation of their knowledge through the BMTCN??? certification. This study manual follows the BMTCN??? test blueprint. Each chapter contains carefully written study questions to use with Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) to prepare nurses for the certification examination. Whether the reader is a nurse on the front line, advanced practitioner, nurse manager, or nurse scientist, this study manual is an important resource for the examination for years to come"--
Read Less
Add this copy of Bmtcn Certification Review Manual to cart. $80.35, good condition, Sold by BooksRun rated 4.0 out of 5 stars, ships from Philadelphia, PA, UNITED STATES, published 2023 by Oncology Nursing Society.
